1 / 14

IAS 2011, Rome, July 17 - 20

Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partum Thu-Ha Dinh, MD., MS., US CDC/GAP. IAS 2011, Rome, July 17 - 20. Overview of Presentation. Background -- Justification of the evaluation Evaluation questions

sian
Télécharger la présentation

IAS 2011, Rome, July 17 - 20

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Generic protocol for national population-based impact evaluation of national programs for PMTCT at 6 weeks post-partumThu-Ha Dinh, MD., MS., US CDC/GAP IAS 2011, Rome, July 17 - 20

  2. Overview of Presentation • Background -- Justification of the evaluation • Evaluation questions • Primary objectives • Who – Where – How • Ethical consideration • Methods • Design • Sample size • Testing algorithms • Procedure • Data management – storage – analysis • Dissemination of findings

  3. PMTCT effectiveness • HIV transmission – proximate purpose of programs is to reduce MTCT of HIV • ARV prophylaxis • Safe feeding • Maternal ART • HIV free survival – ultimate goal of programs is to save children from HIV & death • Time points: • Perinatal and during breast-feeding (6 wks, 6 months, 9 months, 12 months, 18 months, etc)

  4. Why do we need national population estimate? • Overall effectiveness of the program • Assess mother-infant pairs in PMTCT and not reached • Provide unbiased estimate of HIV-infected infants/children

  5. Primary Evaluation Question • What is population-basedperinatal MTCT rate measured at 6 weeks? • What is the HIV exposure prevalence among infants at 6 weeks ? • What is the HIV infection prevalence among infants, 6 weeks • What is the coverage of each PMTCT service along PMTCT cascade?

  6. How we measure HIV exposure prevalence? • Self-reported HIV positive status from mother? • Self-report bias • HCT uptake • Documented HIV positive status of mother during pregnancy? • Information documented • HCT uptake • Identify maternal HIV antibody in targeted infant (biomedical marker) ? • No bias: self-report or HCT uptake or information doc. • Include HIV acquisition • Sensitivity and specificity of the antibody test used

  7. Identify maternal HIV antibody in Infant HIV Abtest Thanks to E. Abram and N. Rollins

  8. Where we can recruit representative sample of the infant population? • At labor and delivery clinic? • Home delivery? • HCT during ANC, L&D • At home – household survey? • HCT during ANC, L&D • Not part of routine - expensive • At immunization clinic? • The 1st immunization coverage >80% • The 1st immunization coverage 70% - 80%  special sample size and sub-study will be required to adjust for findings

  9. Design an Evaluation • Questions objectives  variables needed • Who: inclusion and exclusion, age range (4-8, 6-8?) • Where: to recruit potential participants • Ethical consideration • Design • Cross-sectional design  point estimate (6 weeks) • Sampling frame: • multistage (province, facility)  select facilities • participants from each selected facility (potential participant load systematic or random or consecutive)

  10. Design: Sample size • Estimate HIV prevalence in pregnant women • Estimate ARV uptake among HIV+ pregnant women • Estimate/collect existing MTCT • Specify the appropriate level of precision • Assume a design effect of 2 and double the calculated sample size to take account of cluster sampling

  11. Design: Procedure Eligible caregiver-infants Don't consent to take part in the survey Do consent to take part in the survey Caregiver interview and no infant-DBS Caregiver interview and infant-DBS Standard of care recommended by WHO HIV Ab positive (HIV-exposed infant) HIV Ab Negative (HIV-unexposed infant) HIV DNA PCR positive (HIV-infected infant) HIV DNA PCR negative (HIV uninfected infant)

  12. Consent and interview processcaregivers vs. mothers Decision needs to be based on • Local situation  all legal caregivers • Orphan population • Proportion of mothers who work • Local child Act toward health care right/assess • Community consent  acceptable ? • Precision needed for estimate • Infant benefit vs. Mother benefit • Who should receive test result?  ? validity of findings if caregivers excluded

  13. Design: Data management/Storage/Analysis • Data management: • Quality control: at facility and at survey office • Data entry and safety • Who can access to the data • Ownership of the data • Storage: • Paper-based: when paper-based will be destroyed • Public domain: how and when • Data analysis • Dummy tables  key outcomes • Identify potential bias can be controlled by analysis  collect those variables

  14. Dissemination of findings • Provide feedback to clinics and provinces to improve/scale up program • Provide feedback to provincial DOH and national MOH • Share findings and lessons learned with other donors and organizations • Publish findings on peer review journals

More Related